Health Care Supplies

Sanxin Medtec

Sanxin Medtec released FY2025 Q4 earnings on April 26 During-Market (BJT), actual revenue CNY 472.59 M, actual EPS CNY 0.1543

Sanxin Medtec released FY2025 earnings on April 26 During-Market (BJT), actual revenue CNY 1.64 B, actual EPS CNY 0.5117

Sanxin Medtec released FY2026 Q1 earnings on April 26 After-Market BJT, actual revenue CNY 408.87 M, actual EPS CNY 0.132

Sanxin Medtec FY2026 Q1 Earnings Release on April 27 After-Market (BJT)

Sanxin Medtec to Release FY2025 Earnings Report on April 27 During-Market BJT

Sanxin Medtec released FY2025 9 Months Earnings on October 29 After-Market (BJT), actual revenue CNY 1.168 B, actual EPS CNY 0.3541

Sanxin Medtec released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 406.79 M, actual EPS CNY 0.1336

Sanxin Medtec to Release FY2025 Q3 Earnings on October 30 After-Market (BJT)

Sanxin Medtec released FY2025 Q2 earnings on August 8 Pre-Market (BJT), actual revenue CNY 400.23 M, actual EPS CNY 0.1176

Sanxin Medtec released FY2025 semi-annual earnings on August 8 Pre-Market (BJT), actual revenue CNY 760.81 M, actual EPS CNY 0.2204

Sanxin Medtec FY2025 Semi-Annual Earnings Release on August 9, 2025 (BJT)

Sinocare Responds to Investor Concerns Over R&D Expenses

Sanxin Medical Plans to Set Up a Wholly-Owned Subsidiary in Hong Kong

Subsidiary of Sinsin Medical Obtains Medical Device Registration Certificate

Sanxin Medical Obtains Medical Device Registration for Pre-filled Catheter Irrigation Device

Sanki Medical Takes Multiple Measures in Response to Weigao Blood Purification Listing

Sankin Medical Announces Q1 2025 Earnings Report

Sanxin Medtec released FY2025 Q1 earnings on April 27 During-Market BJT, actual revenue CNY 360.58 M, actual EPS CNY 0.1028

Sanxin Medtec FY2025 Q1 Earnings Release on April 28 During-Market BJT

Sanxin Medical Introduces Obturator Product Registration and Market Competition Status

301122

300453

002382

300677

300981

002950

A-share medical consumables stocks continue to rise, ZHYL and INTCO are approaching a 20% limit-up, Allmed Medical and BLUE SAIL MEDICAL previously hit the limit-up, Sanxin Medtec and CAINA have leading gains

Wallstreetcn

CAINA

BLUE SAIL MEDICAL

INTCO

ZHYL

Allmed Medical

According to the Zhitong Finance APP, Sanxin Medtec released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.168 billion yuan, a year-on-year increase of 7.88%. The net profit attributable to shareholders of the listed company was 185 million yuan, a year-on-year increase of 10.16%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 167 million yuan, a year-on-year increase of 10.09%. The basic earnings per share were 0.3573 yuan

Zhitong

Sanxin Medtec released its performance for the first three quarters, with a net profit attributable to the parent company of 185 million yuan, an increase of 10.16%

300246

Western Securities released a research report indicating that the market for blood dialysis medical devices in China is steadily growing, with a CAGR of 5.67% from 2019 to 2023, and is expected to reach 21.52% from 2023 to 2027. With the increasing number of ESRD patients and the improvement in residents' medical payment capabilities, the demand for dialysis continues to grow. The acceleration of domestic substitution, the recovery of bidding, and the release of overseas potential are characteristics of the industry. The market size for blood dialysis machines, devices, and tubing is expected to grow significantly in the coming years

BIOLIGHT

Fresenius Medical Care

Western Securities: The time for domestic substitution of blood dialysis is right; optimistic about major products, diversification, and overseas expansion

Sanxin Medtec recently obtained the EU Medical Device Regulation (MDR) certification issued by the German Rhine TÜV Group, covering four products including disposable sterile injection needles, retractable self-destructing sterile syringes, precision filter infusion sets, and infusion sets. This certification indicates that the company has established a quality management system in compliance with EU MDR regulations, marking that the products meet the latest regulatory requirements, which will aid in promotion and sales in the EU and other countries that recognize MDR certification, enhancing global market competitiveness

Sanxin Medtec: Four products obtained EU MDR certification

Sanxin Medtec announced that its holding subsidiary Chengdu Weili Sheng Biological Technology Co., Ltd. has changed the production scope of its medical device manufacturing license to adapt to the adjustments of the "Medical Device Classification Catalog." The new license was reissued by the Sichuan Provincial Drug Administration, with the number Chuan Yao Jian Xie Sheng Chan Xu 20160053, covering Class II and Class III blood purification and peritoneal dialysis equipment, with a validity period from December 10, 2020, to December 9, 2025. This change has no significant impact on the company's production and operations

Sanxin Medtec: The holding subsidiary has changed the medical device production license

688273

688085

688029

688108

300314

The medical device sector has risen again, with SINOMED, David Medical, MEDLANDER, and Sanxin Medtec increasing by over 10%, while Sanyou Medical and MTM also followed suit

MEDLANDER

Sanyou Medical

SINOMED

David Medical

Sanxin Medtec plans to issue convertible corporate bonds to unspecified objects, with a total fundraising amount not exceeding 530 million yuan. The raised funds will be used for the renovation and expansion project of an annual production capacity of 10 million bundles of hemodialysis membranes and instruments, the construction of a high-performance blood purification equipment research and production base, and to supplement working capital. The initial conversion price will be based on the average trading price of the company's stock

Sanxin Medtec plans to issue convertible bonds to raise no more than 530 million yuan

Sanxin Medtec released its semi-annual report for 2025, with operating revenue of 761 million yuan, a year-on-year increase of 10.83%; net profit attributable to the parent company was 115 million yuan, a year-on-year increase of 8.35%. The net profit excluding non-recurring gains and losses was 103 million yuan, a year-on-year increase of 9.26%. The basic earnings per share were 0.2207 yuan, and the company plans to distribute a cash dividend of 1 yuan for every 10 shares to all shareholders. The company continues to expand its market and improve performance through a full product chain layout and moat advantages

Sanxin Medtec released its performance for the first half of the year, with a net profit attributable to the parent company of 115 million yuan, an increase of 8.35%

Sanxin Medtec plans to establish a wholly-owned subsidiary in Hong Kong with an investment amount of USD 100,000 and a registered capital of USD 100,000. This move aims to strengthen cooperation with international markets, expand overseas business, and aligns with the company's development strategy, having a positive impact on long-term development and strategic layout

Sanxin Medtec plans to establish a wholly-owned subsidiary in Hong Kong

Sanxin Medtec's subsidiary Chengdu Weili Sheng Biological Technology Co., Ltd. recently obtained the "Medical Device Registration Certificate" issued by the Sichuan Provincial Drug Administration, involving the product "Mobile Water Treatment System for Blood Dialysis." This system consists of multiple filters, softeners, reverse osmosis devices, etc. The acquisition of this registration certificate will further improve the company's product chain in the field of blood purification medical equipment and have a positive impact on future production and operations

Sanxin Medtec's subsidiary obtains medical device registration certificate for mobile blood dialysis water treatment system

Sanxin Medtec(300453.SZ)